has function has role vaccinated in route immunizes against disease immunizes recipient cancer Homo sapiens RNA vaccine intramuscular route therapeutic vaccine function vaccine in clinical trial role RNA vaccine role therapeutic cancer vaccine mRNA-based personalized cancer vaccine NCI-4650 NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148239 6324 Jie Zheng A cancer vaccine targeting up to fifteen tumor-associated antigens (TAAs) that are specifically expressed by a patient's cancer cells, with potential immunostimulatory and antineoplastic activities. Up to fifteen neoantigen epitopes are incorporated in a proprietary formulation designed to maximize mRNA delivery and minimize mRNA-triggered immune responses. The mRNA-based PCV NCI-4650 is taken up and the mRNAs are translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This induces both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens. Exome sequencing can identify certain gene mutations in a person's tumor. This can then be used to create cancer treatments. This mRNA vaccine might cause certain tumors to shrink. Immunogenic neoantigens and can predict for neoantigens binding the patient human leukocyte antigen (HLA) molecules from melanoma or epithelial cancer patients and use these epitopes for a personalized therapeutic messenger ribonucleic acid (mRNA) vaccine. cancer vaccine Hayleigh Kahn VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6324 NCT: https://clinicaltrials.gov/study/NCT03480152